H.C. Wainwright Sticks to Their Buy Rating for Co-Diagnostics (CODX)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Co-Diagnostics (CODXResearch Report), with a price target of $9.00. The company’s shares closed last Friday at $4.48.

According to TipRanks, Chen is an analyst with an average return of -6.7% and a 36.07% success rate. Chen covers the Healthcare sector, focusing on stocks such as Prophase Labs, Veru, and Co-Diagnostics.

Currently, the analyst consensus on Co-Diagnostics is a Moderate Buy with an average price target of $7.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $11.82 and a one-year low of $3.66. Currently, Co-Diagnostics has an average volume of 615.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company’s products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Read More on CODX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More